- Oops!Something went wrong.Please try again later.
Therapeutic and diagnostic Morphomers™ enable AC Immune’s unique precision medicine approach for neurodegenerative diseases
Webinar will take place on Wednesday, March 31, 2020 at 10:00 AM ET
LAUSANNE, Switzerland, March 26, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will host a corporate update webinar on Wednesday, March 31st at 10:00 AM ET until 11:30 AM ET.
During the webinar, members of the AC Immune Management and Research and Development Teams will discuss the unique benefits of the Company’s innovative Morphomer™ technology platform, which accelerates the design, synthesis, and development of CNS-optimized, conformation-specific small molecules directed against pathological proteins. The platform has produced multiple clinically validated therapeutic and diagnostic candidates that bind selectively to target proteins intracellularly, at the earliest stages of disease.
The current Morphomer™ pipeline includes two clinical-stage diagnostic candidates (Tau-PET tracer and alpha-synuclein-PET tracer), and one therapeutic candidate that has completed Phase 1 (Morphomer™ Tau ACI-3024). Additional first-in-class Morphomer™-derived therapeutic and diagnostic candidates targeting Tau, alpha-synuclein, TDP-43 and NLRP3-ASC are in preclinical development. Together with the Company’s SupraAntigen™-derived therapeutic antibody and vaccine candidates, AC Immune’s comprehensive Morphomer™ pipeline enables a differentiated Precision Medicine approach against multiple key proteins by pairing the Company’s targeted therapeutics with proprietary companion diagnostics.
Following the formal presentations, there will be an interactive virtual roundtable discussion between the audience and the AC Immune Management and Research and Development Teams.
Andrea Pfeifer, Ph.D.
Chief Executive Officer
Marie Kosco-Vilbois, Ph.D.
Chief Scientific Officer
Sonia Poli, Ph.D.
Life Cycle Leader
Francesca Capotosti, Ph.D.
Group Leader, In vivo Pharmacology and Non-Clinical Safety
About AC Immune SA
AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigenTM and MorphomerTM, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features nine therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.
For further information, please contact:
Head of Investor Relations
European Investors & Media
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.